CDNA:NSD-CareDx, Inc (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 75.89

Change

+0.67 (+0.89)%

Market Cap

USD 3.71B

Volume

0.42M

Average Target Price

USD 81.88 (+7.89%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-22 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

+5.09 (+1.26%)

USD58.82B 90.54 52.60
IDXX IDEXX Laboratories, Inc

+5.18 (+0.96%)

USD46.33B 80.64 58.00
DXCM DexCom, Inc

+8.76 (+2.18%)

USD38.84B 79.37 100.37
EXAS Exact Sciences Corporation

+1.22 (+0.95%)

USD21.77B N/A N/A
GH Guardant Health, Inc

+2.91 (+1.90%)

USD15.01B N/A N/A
OZON Ozon Holdings PLC

+0.84 (+1.37%)

USD12.45B N/A N/A
ICLR ICON Public Limited Company

+1.71 (+0.81%)

USD10.89B 33.55 22.56
PRAH PRA Health Sciences, Inc

+0.67 (+0.41%)

USD10.50B 53.51 26.30
NTRA Natera, Inc

-2.67 (-2.44%)

USD9.50B N/A N/A
SYNH Syneos Health, Inc

+0.76 (+0.86%)

USD8.88B 46.57 23.07

ETFs Containing CDNA

Symbol Name Weight Mer Price(Change) Market Cap
GNOM Global X Genomics & Biote.. 0.00 % 0.50 %

+0.17 (+0.76%)

USD0.20B

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.75% 39% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.75% 39% F 45% F
Trailing 12 Months  
Capital Gain 215.16% 86% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 215.16% 86% B 87% B+
Trailing 5 Years  
Capital Gain 1,636.61% 95% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,636.61% 95% A 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 209.80% 95% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 209.80% 95% A 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 305.84% 9% F 4% F
Risk Adjusted Return 68.60% 74% C 83% B
Market Capitalization 3.71B 74% C 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 13.86 20% F 12% F
Price / Cash Flow Ratio 110.93 12% F 5% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -9.94% 64% D 43% F
Return on Invested Capital -11.41% 59% F 32% F
Return on Assets -5.41% 61% D- 33% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.57 16% F 16% F
Short Percent 11.60% 19% F 18% F
Beta 0.64 80% B- 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.